• Home
  • MyECTS
  • Become a member
  • Contact us

Ectsoc

Ecstoc.org

MENUMENU
  • About
    • Mission & Vision
    • Governance & Transparency
    • Board of Directors
    • Annual General Meeting
    • Committees and Action Groups
      • Executive Committee
      • Communications Committee
      • Community Engagement Committee
      • ECTS Academy
      • Education Committee
      • Clinical Science Committee
      • Research Committee
      • Scientific Programme Committee 2025
    • ECTS Team
    • Membership
      • Individual Membership
      • Corporate Supporters
      • Join us
      • Affiliated Societies
  • ECTS 2025
  • Events
    • Upcoming Congresses
    • Past Congress
    • ECTS Academy Charity Event
    • ICCBH
    • Events
  • Grants & Awards
  • Education
    • PhD Training Course
    • Clinical Training Course in Metabolic Bone Diseases
    • Rare Bone Diseases Webinars
    • Education Resource Center
    • Bone Muscle & Beyond Webinars
    • ECTS-Mellanby Training Course
    • Calendar ECTS Educational Events
  • ECTS Academy
    • About the ECTS Academy
    • ECTS Academy – Members
    • Call for Applications - Basic Scientists
    • Call for Applications - Clinicians
    • ECTS Academy Activities
      • NI Conference Program
      • ECTS Academy Webinar Series
      • ECTS Academy Mentoring Options
      • ECTS Academy Charity Run
    • Visit the ECTS Academy website
  • News
    • ECTS Newsletter
    • News
    • Press Release
    • Image Library
    • Video Library
    • Job Advertisements
You are here: Home / Education / E-learning / ECTS Webinar Series Bone, Muscle & Beyond / Webinar Series Rare Bone Diseases: Polyostotic Fibrous Dysplasia

Webinar Series Rare Bone Diseases: Polyostotic Fibrous Dysplasia

Live Webinar: 12 January 2022, 4-5 pm CET

Organiser: European Calcified Tissue Society

Sponsored by Industry

Featuring Prof Roland Chapurlat, moderated by Heide Siggelkow & Thomas Funck-Brentano

Costs: Live & On-demand webinar is free for ECTS members and non-members, but a registration is required.

REGISTER FOR THE WEBINAR

Format:

  • 5 min introduction
  • 25 min meet-the-expert presentation
  • 30 min Q&A and Case Discussion

Learning Objectives:

  • Understanding what is FD/MAS
  • How to make the diagnosis of FD/MAS
  • How to manage patients with FD/MAS

 

Accreditation:

The ECTS Rare Bone Diseases Webinar – Polyostotic Fibrous Dysplasia, Brussels, Belgium, 12/01/2022-12/01/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s).

Each medical specialist should claim only those credits that he/she actually spent in the educational activity, live or on-demand.  To obtain your Certificate, you will be required to fill in a short feedback evaluation form.

 

Register for the Webinar

Chairs & Speaker

Featuring Prof. Dr. Roland Chapurlat

Dr Roland Chapurlat has been a Professor of Rheumatology at the University Claude Bernard-Lyon 1 since 2005. He is the Chief of the Division of Rheumatology and Bone Diseases at Edouard Herriot Hospital In Lyon France and the head of the Department of medicine in this same hospital. Dr Chapurlat is also leading the team “Bone and chronic diseases” at INSERM UMR 1033 and a reference center for rare bone diseases in Lyon, France. His main research interests are osteoporosis, osteoarthritis and rare bone diseases such as fibrous dysplasia of bone and osteogenesis imperfecta. He has published more than 250 articles in peer-reviewed journals.

Dr Thomas Funck-Brentano, Chair

Dr Heide Siggelkow, Chair

Abstract

Breast cancer cells frequently disseminate to the bone marrow, where they may either enter a dormant state or colonize the bone and induce osteolysis. The mechanisms that regulate tumor cell entry and exit from dormancy in the bone are not well understood, but several factors have been identified. Previous work from our group found that leukemia inhibitory factor receptor (LIFR) promotes tumor dormancy when expressed on bone-disseminated tumor cells and that loss of LIFR enables otherwise dormant tumor cells to colonize the bone. Our lab has therefore examined how LIFR expression is regulated in breast cancer cells, with the hope that understanding its regulation might provide novel avenues to therapeutically target dormant disseminated tumor cells. Through these efforts we have found that LIFR is epigenetically regulated, and that histone deacetylase (HDAC) inhibitors, which are FDA-approved for several blood cancers, stimulate LIFR expression on breast cancer cells from all subtypes. This finding presents an interesting therapeutic opportunity to explore whether HDAC inhibitors may be used to promote a chronic state of tumor dormancy and prevent recurrence in bone. Our findings suggest that this may be feasible, but that the effects of histone deacetylase inhibitors on bone remodeling profoundly impact tumor colonization and must be combined with appropriate anti-resorptive therapies.

Copyright 2016 ECTS - Disclaimer - Cookies Policy - Privacy Policy - Privacy Centre - Terms of use - Contact us